课题基金 / 基金详情

Comparative Safety of Benzodiazepines and Opioids Among VA Patients with PTSD

Comparative Safety of Benzodiazepines and Opioids Among VA Patients with PTSD
苯二氮卓类药物和阿片类药物在患有 PTSD 的 VA 患者中的安全性比较
批准号:
8676423
负责人:
Eric Hawkins
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-01 至 2016-09-30

项目摘要

项目成果

Eric Hawkins的其他基金

相似基金

相关文献

中文摘要
翻译
项目背景。创伤后应激障碍(PTSD)是一种常见的心理健康状况, 2010年,500,000名退伍军人事务部(VA)患者被诊断为创伤后应激障碍。显著的死亡率和发病率 与创伤后应激障碍相关的疾病强调了对这一人群进行安全有效治疗的重要性。 大量患有创伤后应激障碍的退伍军人表现出多种复杂的症状,如 出现疼痛、焦虑和失眠,通常是处方阿片类药物和苯二氮卓类药物 治疗这些症状。然而,阿片类药物和苯二氮卓类药物之间的潜在相互作用对 服用它们的患者,具有最严重的风险,包括因过度镇静和 死于呼吸抑制。尽管有这些已知的风险,但关于全国范围内的 阿片类药物和苯二氮卓类药物同时使用的流行率,在风险较高的患者中使用 严重不良事件,如有问题的饮酒、自杀风险和高龄,或 在被诊断为创伤后应激障碍的患者中比较这些药物的安全性。 项目目标。该项目的具体目标包括:1)估计每年任何 慢性阻塞性肺疾病患者同时使用阿片类药物和苯二氮卓类药物30天和长期(90天) 有记录的创伤后应激障碍,1b)估计酒精滥用、自杀风险和老年人的年度流行率 同时服用苯二氮卓类药物和阿片类药物的PTSD患者,2)评估VA 同时接受阿片类药物和苯二氮卓类药物治疗的创伤后应激障碍患者患各种原因的风险增加 死亡率和骨折,与仅接受阿片类药物、仅接受苯二氮卓类药物和不使用阿片类药物的人相比 这些药物,以及3)测试酒精滥用和高龄是否与ALL风险增加相关 服用阿片类药物和苯二氮类药物的创伤后应激障碍患者死亡和骨折原因分析 同时,与那些酒精滥用筛查阴性或65岁的人相比。 项目方法。这项建议的回溯性队列研究将使用退伍军人管理局公司数据中的数据 仓库(CDW)和VA-CMS(Medicare和Medicaid)数据集,用于评估不良事件和VHA VITAL 用于评估死亡率的状态文件。符合条件的参与者在退伍军人管理局接受治疗,并被诊断为患有 2010-2011财年的创伤后应激障碍诊断。目标1a将使用性别特定的逻辑回归来 估计任何(>30天)和长期(>90天)同时使用阿片类药物和 接受VA护理并被诊断为创伤后应激障碍的患者中的苯二氮卓类药物。目标1b将使用特定性别 估计酒精滥用、自杀风险和高龄患病率的Logistic回归分析(>65 同时使用阿片类药物和苯二氮卓类药物的人)。目标2将估计死亡率的相对风险 2011-2012财年新同时使用阿片类药物和苯二氮卓类药物的患者中发生骨折的人数与 倾向性评分仅与苯二氮卓类药物使用者、阿片类药物使用者和不使用这些药物的人匹配, 使用COX比例回归模型中的风险比。目标3将测试是否所有风险都会导致死亡 同时服用阿片类药物和苯二氮卓类药物的患者发生骨折 COX比例回归模型分析表明,酒精滥用和高龄并存增加了患者的酒精率。 影响。从这项提案中获得的知识将支持退伍军人管理局努力发展国家提供商级别的 阿片类药物监测系统,以减少非推荐处方做法,包括同时开药 阿片类药物和苯二氮卓类药物,通过确定不良事件风险较大的人群亚组。 结果将教育患者和提供者关于两个最重要的不良事件,死亡 以及与这些药物相关的骨折,从而为临床护理决策提供信息。此外,调查结果 将提供开发计算机化临床决策支持干预措施所需的关键信息 旨在教育患者和提供者与这些药物相关的风险。
英文摘要
Project Background. Posttraumatic stress disorder (PTSD) is a common mental health condition, with over 500,000 Veteran Affairs (VA) patients diagnosed with PTSD in 2010. The significant mortality and morbidity associated with PTSD underscore the importance of safe and effective treatments for this population. Substantial numbers of Veterans with PTSD present with multiple and complex symptomatology such as co- occurring pain, anxiety and insomnia, and are commonly prescribed opioid and benzodiazepine medications to treat these symptoms. Yet, potential interactions between opioids and benzodiazepines pose serious risks to patients who take them, with the most serious risks including fall-related injuries caused by over-sedation and death due to respiratory depression. Despite these known risks, limited information exists on the national prevalence of opioids and benzodiazepines prescribed concurrently, their use among patients at elevated risk of severe adverse events, such as those with problematic alcohol use, suicide risk and advanced age, or the comparative safety of these medications among those diagnosed with PTSD. Project Objectives. The specific aims of this project include to 1a) estimate the annual prevalence of any (>30-days) and long-term (>90-days) concurrent opioid and benzodiazepine use among patients with documented PTSD, 1b) estimate the annual prevalence of alcohol misuse, suicide risk and the elderly among patients with PTSD who are prescribed benzodiazepines and opioids concurrently, 2) assess whether VA patients with PTSD receiving opioids and benzodiazepines concurrently are at increased risk of all cause mortality and fractures, as compared to those receiving opioids only, benzodiazepines only and nonusers of these medications, and 3) test if alcohol misuse and advanced age are associated with increased risks of all cause mortality and fractures among VA patients with PTSD who are prescribed opioids and benzodiazepines concurrently, as compared to those who screen negative for alcohol misuse or who are <65 years old. Project Methods. This proposed retrospective cohort study will use data from the VA's Corporate Data Warehouse (CDW) and VA-CMS (Medicare and Medicaid) datasets to assess adverse events and VHA Vital Status Files to assess mortality. Eligible participants received care at a VA facility and were diagnosed with a PTSD diagnosis during fiscal years (FY) 2010-2011. Aim 1a will use gender-specific logistic regressions to estimate the annual prevalence of any (>30-days) and long-term (>90-days) concurrent use of opioids and benzodiazepines among patients receiving VA care and diagnosed with PTSD. Aim 1b will use gender-specific logistic regressions to estimate the prevalence of comorbid alcohol misuse, suicide risk and advance age (> 65 years old) among concurrent opioid and benzodiazepine users. Aim 2 will estimate the relative risk of mortality and fractures in FY 2011-2012 among new concurrent opioid and benzodiazepine users, as compared to propensity score matched users of benzodiazepines only, opioids only and nonusers of these medications, using hazard ratios from Cox proportional regression models. Aim 3 will test if the risks of all cause mortality and fractures among patients who are newly prescribed opioids and benzodiazepines concurrently are increased due to comorbid alcohol misuse and advanced age using Cox proportional regression models. Impacts. Knowledge gained from this proposal will support VA efforts to develop a national provider-level opioid surveillance system to reduce non-recommended prescribing practices, including concurrent prescribing of opioids and benzodiazepines, by identifying subsets of the population at greater risk of adverse events. Results will educate patients and providers with respect to two of the most important adverse events, death and fractures, associated with these medications, thereby informing clinical care decisions. Further, findings will provide critical information needed for development of computerized clinical decision support interventions designed to educate patients and providers about risks associated with these medications.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Evaluating the Implementation of the VA Stepped Care for Opioid Use Disorder Train-the-Trainer (SCOUTT) Program
TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT
Collaborative Care Management for Complex, Recurrent Substance Use Disorders
TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT
海外基金